Orphan status for treatment of renal cell carcinoma granted by FDA. Cetus, which has been studying the recombinant interleukin-2 product in a number of cancers, says it will file a Proleukin PLA before 1989, but has not disclosed what claims it will seek. Roche, which is developing an Immunex IL-2 product, is also near the PLA submission stage and, like Cetus, has not publicly announced what indications it is interested in. However, at a recent analyst meeting, Immunex Chairman Stephan Duzan noted that the best clinical responses of IL-2 have been observed in renal cell carcinoma and melanoma.
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.